izpis_h1_title_alt

PPIA, HRPT1, and PGK1 genes as the appropriate combination for RT-qPCR normalization in alveolar and femoral bone remodeling in olanzapine-treated rats
ID Disha Ibrahimi, Saranda (Author), ID Drevenšek, Gorazd (Author), ID Drevenšek, Martina (Author), ID Marc, Janja (Author), ID Prodan Žitnik, Irena (Author)

.pdfPDF - Presentation file, Download (1,27 MB)
MD5: B47BDD6B7DE4F437C3D7F7709619697F
URLURL - Source URL, Visit https://acta.pharmaceutica.farmaceut.org/wp-content/uploads/2024/09/51124.pdf This link opens in a new window

Abstract
Reliable gene expression analysis in bone remodeling studies requires an appropriate selection of internal controls, i.e. stable reference genes for the normalization of quantitative real-time PCR (RT-qPCR), the most common method used for quantifying gene expression measurements. Even the most widely used reference genes can have variable expression under different experimental conditions, or in different tissue types or treatment regimes, so selecting appropriate controls is a key step in ensuring reliable results. The aim of this research was to identify the most stable reference gene(s) for the study of olanzapine modulated bone remodeling in rats. RNA was isolated from the maxillary alveolar and femoral bones of olanzapine or placebo-treated Wistar rats and transcribed to cDNA. The expression of 12 candidate reference genes was assessed by RT‐qPCR. Their expressions were analysed using GeNorm, NormFinder, BestKeeper and delta Ct algorithms, and by the comprehensive ranking method. PPIA, HRPT1 and PGK1 were the most stably expressed reference genes and the combination of the three genes was optimal for normalization. This study is the first to identify the optimal reference genes for research in olanzapine-exposed rats, which serve as a pivotal benchmark for enhancing the accuracy and reliability of future RT-qPCR expression in bone studies.

Language:English
Keywords:reference genes, alveolar bone, RT-qPCR, rat, olanzapine
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
MF - Faculty of Medicine
Publication version:Version of Record
Year:2024
Number of pages:Str. 511-524
Numbering:Vol. 74, no. 3
PID:20.500.12556/RUL-163546 This link opens in a new window
UDC:602.64:616
ISSN on article:1846-9558
DOI:10.2478/acph-2024-0029 This link opens in a new window
COBISS.SI-ID:206027523 This link opens in a new window
Publication date in RUL:08.10.2024
Views:75
Downloads:7
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Acta pharmaceutica
Shortened title:Acta pharm.
Publisher:Croatian Pharmaceutical Society
ISSN:1846-9558
COBISS.SI-ID:3817585 This link opens in a new window

Licences

License:CC BY-ND 4.0, Creative Commons Attribution-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nd/4.0/
Description:Under the NoDerivatives Creative Commons license one can take a work released under this license and re-distribute it, but it cannot be shared with others in adapted form, and credit must be provided to the author.

Secondary language

Language:Slovenian
Keywords:referenčni geni, alveolarna kost, RT-qPCR, podgane, olanzapin, genska terapija, gensko izražanje

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0293
Name:Parodontalna medicina

Funder:Other - Other funder or multiple funders
Project number:AD FUTURA
Name:AD FUTURA. Science and Education Foundation of the Republic of Slovenia,

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back